AI summary · may contain errors
In the PECATI phase 2 trial for platinum-refractory advanced B3-thymoma and thymic carcinoma, median progression-free survival reached 22.1 months with 88.0% 5-month PFS.
Moving in JAMA Dermatology, Annals of the Rheumatic Diseases, Arthritis & Rheumatology, JAMA Neurology, The Lancet Neurology, American Journal of Respiratory and Critical Care Medicine, Annals of Oncology and Autophagy.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
In the PECATI phase 2 trial for platinum-refractory advanced B3-thymoma and thymic carcinoma, median progression-free survival reached 22.1 months with 88.0% 5-month PFS.
AI summary · may contain errors
Unsupervised clustering of 2,035 anti-synthetase syndrome (ASyS) cases in the CLASS project database identified three ASyS phenotypic subgroups, including an ILD-predominant group (n = 581).
AI summary · may contain errors
Low-dose blinatumomab given as 2 cycles by continuous intravenous infusion in 2 patients (anti-Mi-2-positive dermatomyositis and refractory ANCA-associated vasculitis) showed rapid T-cell activation and B-cell depletion with clinical improvement.
AI summary · may contain errors
Antibody-mediated glial disorders targeting aquaporin-4 and myelin oligodendrocyte glycoprotein are distinct nosological entities with specific targets, mechanisms, syndromes, and treatment implications.
AI summary · may contain errors
Add-on intravenous immunoglobulin (IVIG) given at 0, 4, and 8 weeks improves myositis activity at week 12 in newly diagnosed adult idiopathic inflammatory myopathies, raising Total Improvement Score to 60.0 vs 42.5 with P=.01.
AI summary · may contain errors
Low-dose interleukin-2 restores CD25hi regulatory T cells in patients with active polymyositis/dermatomyositis, with reduced Treg-IL-2 axis markers compared with healthy controls.
AI summary · may contain errors
Inebilizumab reduced exacerbation risk in randomized phase 3 myasthenia gravis (gMG) patients, with hazard ratios of 0.41 by week 26 overall.
Journals this month
Topics moving, week to 17 Nov 2026
By field